| 2.1 -0.23 (-9.87%) | 10-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.76 |
1-year : | 3.09 |
| Resists | First : | 2.36 |
Second : | 2.65 |
| Pivot price | 2.24  |
|||
| Supports | First : | 1.9 |
Second : | 1.58 |
| MAs | MA(5) : | 2.33 |
MA(20) : | 2.18 |
| MA(100) : | 2.47 |
MA(250) : | 5.57 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 45.4 |
D(3) : | 63.8 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 16.7 | Low : | 1.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INAB ] has closed above bottom band by 30.7%. Bollinger Bands are 43.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.51 - 2.53 | 2.53 - 2.54 |
| Low: | 2.27 - 2.29 | 2.29 - 2.31 |
| Close: | 2.31 - 2.33 | 2.33 - 2.35 |
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Thu, 07 Aug 2025
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Yahoo Finance
Mon, 30 Jun 2025
IN8bio Regains Nasdaq Compliance with Bid Price Rule - TipRanks
Mon, 30 Jun 2025
IN8bio regains compliance with Nasdaq minimum bid price requirement - Investing.com
Wed, 04 Jun 2025
IN8bio Announces 1-for-30 Reverse Stock Split - TipRanks
Mon, 12 May 2025
IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary - GlobeNewswire
Tue, 29 Apr 2025
IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 19.2 (%) |
| Shares Short | 65 (K) |
| Shares Short P.Month | 71 (K) |
| EPS | -9.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.74 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -69.1 % |
| Return on Equity (ttm) | -165.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.24 |
| PEG Ratio | 0 |
| Price to Book value | 0.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|